Kayentis has announced a new executive appointment of Guy Maestre as Vice President U.S. Operations.
Kayentis, a global provider of digital pen and paper technology
and the unique provider of “paper based e-trial” solutions, today announced a new executive appointment of Guy Maestre as Vice President U.S. Operations, therefore continuing and strengthening its expansion in North America.
Philadelphia, PA / Gif sur Yvette, France — December 4th, 2008
Kayentis, a global leader of digital pen and paper technology, is the unique provider of “paper based e-trials” solution for the Life Sciences industry, offering the easiest data collection method possible for both patients and physicians (pen & paper) combined with all the benefits of electronic data management (accurate timestamps, audit trail functionalities, real-time access, alerts, etc.). In order to continue strengthening its expansion in North America, Kayentis today announced a key appointment and welcomes Guy Maestre to the newly created position of Vice President U.S. Operations effective October 6th, 2008.
Mr. Maestre is a highly recognized professional with over 20 years of biopharmaceutical industry experience with an emphasis on general management, as well as the development and marketing of new drugs on a global basis. Most recently he was
Chief Executive Officer
at PhenoTech Inc., a privately held biopharmaceutical company based in Philadelphia specialized in the discovery, development and commercialization of innovative diagnostic products used in blood banks. Prior to this, Mr. Maestre served as President and CEO of Novactyl, an early stage biotech company developing various anti-infective products where he led the company through successful funding, licensing and development activities. Other prior functions include working at Wyeth and G. D. Searle & Co.
Philippe Berna, Kayentis CEO, commented:
“Developing our presence in the US is a normal step to answer our customers’ needs and better serve them, by offering solutions which cover all their needs at each stage of the drug life cycle :
R&D, Pre-Clinical, Clinical, Post-Market and Sales. We are delighted to appoint someone with Guy’s experience and background to this position. This addition reflects very well our commitment to maximize the potential of our US operations. It answers perfectly our desire to continue expanding the growing interest Kayentis solutions has in the US”
.
“Kayentis has developed Clin’Form®
, a very innovative solution for the data capture of Clinical Report Forms and Patient Diaries, successfully implemented in more than 40 countries for 10 000 users (patients, physicians and CRAs)
,” said Guy Maestre. “
Clin’Form® combines the simplicity of traditional pen and paper data capture with the sophistication of Electronic Data Capture (EDC) treatment of the information. This approach provides significant benefits to the biopharmaceutical industry, the physicians and the patients for the implementation of clinical trials. I am very excited to be joining Kayentis to help build our North American operations and to promote this innovative solution to the medical community
.”
Mr. Maestre has an MBA from ESSEC (Ecole Supérieure des Sciences Economiques et Commerciales), has graduated from IPIM, (the Institut de Pharmacie Industrielle) in France and has received his pharmacist degree from the “Université de Pharmacie” in Montpellier, France.
ABOUT KAYENTIS
Kayentis is the leading provider of Digital Pen & Paper (DPP) solutions for the clinical trial industry. Built on the Forms Automation System (FAS) architecture, the Clin’Form® solution allows for all data written using a digital pen and paper, enabling Anoto functionality, to be recorded in an information system and shared via a secure web portal. This cutting-edge solution combines the ease of use of paper with the high technology tools offered by the digital world.
Kayentis is HP Solution Business Partner and Anoto Platinum Partner.
To discover more about this unique solution please visit www.kayentis.com
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.